UroGen Pharma (URGN) PT Raised to $53.50 at Ladenburg Thalmann
Tweet Send to a Friend
Ladenburg Thalmann analyst Matthew Kaplan raised the price target on UroGen Pharma (NASDAQ: URGN) to $53.50 (from $48.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
